Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease: JACC Scientific Expert Panel

Victor J. Del Brutto, Seemant Chaturvedi, Hans Christoph Diener, Jose G Romano, Ralph L Sacco

Research output: Contribution to journalReview article

Abstract

Stroke survivors carry a high risk of recurrence. Antithrombotic medications are paramount for secondary prevention and thus crucial to reduce the overall stroke burden. Appropriate antithrombotic agent selection should be based on the best understanding of the physiopathological mechanism that led to the initial ischemic injury. Antiplatelet therapy is preferred for lesions characterized by atherosclerosis and endothelial injury, whereas anticoagulant agents are favored for cardiogenic embolism and highly thrombophilic conditions. Large randomized controlled trials have provided new data to support recommendations for the evidence-based use of antiplatelet agents and anticoagulant agents after stroke. In this review, the authors cover recent trials that have altered clinical practice, cite systematic reviews and meta-analyses, review evidence-based recommendations based on older landmark trials, and indicate where there are still evidence-gaps and new trials being conducted.

Original languageEnglish (US)
Pages (from-to)786-803
Number of pages18
JournalJournal of the American College of Cardiology
Volume74
Issue number6
DOIs
StatePublished - Aug 13 2019

Fingerprint

Cerebrovascular Disorders
Stroke
Anticoagulants
Fibrinolytic Agents
Platelet Aggregation Inhibitors
Wounds and Injuries
Secondary Prevention
Embolism
Meta-Analysis
Atherosclerosis
Therapeutics
Randomized Controlled Trials
Recurrence

Keywords

  • anticoagulants
  • antiplatelets
  • antithrombotics
  • ischemic stroke
  • secondary prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease : JACC Scientific Expert Panel. / Del Brutto, Victor J.; Chaturvedi, Seemant; Diener, Hans Christoph; Romano, Jose G; Sacco, Ralph L.

In: Journal of the American College of Cardiology, Vol. 74, No. 6, 13.08.2019, p. 786-803.

Research output: Contribution to journalReview article

@article{9b73d16938d04c7eb09ba911c5dd36bc,
title = "Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease: JACC Scientific Expert Panel",
abstract = "Stroke survivors carry a high risk of recurrence. Antithrombotic medications are paramount for secondary prevention and thus crucial to reduce the overall stroke burden. Appropriate antithrombotic agent selection should be based on the best understanding of the physiopathological mechanism that led to the initial ischemic injury. Antiplatelet therapy is preferred for lesions characterized by atherosclerosis and endothelial injury, whereas anticoagulant agents are favored for cardiogenic embolism and highly thrombophilic conditions. Large randomized controlled trials have provided new data to support recommendations for the evidence-based use of antiplatelet agents and anticoagulant agents after stroke. In this review, the authors cover recent trials that have altered clinical practice, cite systematic reviews and meta-analyses, review evidence-based recommendations based on older landmark trials, and indicate where there are still evidence-gaps and new trials being conducted.",
keywords = "anticoagulants, antiplatelets, antithrombotics, ischemic stroke, secondary prevention",
author = "{Del Brutto}, {Victor J.} and Seemant Chaturvedi and Diener, {Hans Christoph} and Romano, {Jose G} and Sacco, {Ralph L}",
year = "2019",
month = "8",
day = "13",
doi = "10.1016/j.jacc.2019.06.039",
language = "English (US)",
volume = "74",
pages = "786--803",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease

T2 - JACC Scientific Expert Panel

AU - Del Brutto, Victor J.

AU - Chaturvedi, Seemant

AU - Diener, Hans Christoph

AU - Romano, Jose G

AU - Sacco, Ralph L

PY - 2019/8/13

Y1 - 2019/8/13

N2 - Stroke survivors carry a high risk of recurrence. Antithrombotic medications are paramount for secondary prevention and thus crucial to reduce the overall stroke burden. Appropriate antithrombotic agent selection should be based on the best understanding of the physiopathological mechanism that led to the initial ischemic injury. Antiplatelet therapy is preferred for lesions characterized by atherosclerosis and endothelial injury, whereas anticoagulant agents are favored for cardiogenic embolism and highly thrombophilic conditions. Large randomized controlled trials have provided new data to support recommendations for the evidence-based use of antiplatelet agents and anticoagulant agents after stroke. In this review, the authors cover recent trials that have altered clinical practice, cite systematic reviews and meta-analyses, review evidence-based recommendations based on older landmark trials, and indicate where there are still evidence-gaps and new trials being conducted.

AB - Stroke survivors carry a high risk of recurrence. Antithrombotic medications are paramount for secondary prevention and thus crucial to reduce the overall stroke burden. Appropriate antithrombotic agent selection should be based on the best understanding of the physiopathological mechanism that led to the initial ischemic injury. Antiplatelet therapy is preferred for lesions characterized by atherosclerosis and endothelial injury, whereas anticoagulant agents are favored for cardiogenic embolism and highly thrombophilic conditions. Large randomized controlled trials have provided new data to support recommendations for the evidence-based use of antiplatelet agents and anticoagulant agents after stroke. In this review, the authors cover recent trials that have altered clinical practice, cite systematic reviews and meta-analyses, review evidence-based recommendations based on older landmark trials, and indicate where there are still evidence-gaps and new trials being conducted.

KW - anticoagulants

KW - antiplatelets

KW - antithrombotics

KW - ischemic stroke

KW - secondary prevention

UR - http://www.scopus.com/inward/record.url?scp=85069929133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069929133&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2019.06.039

DO - 10.1016/j.jacc.2019.06.039

M3 - Review article

C2 - 31395130

AN - SCOPUS:85069929133

VL - 74

SP - 786

EP - 803

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 6

ER -